Terazosin for benign prostatic hyperplasia.

Keyphrases

• Benign Prostatic Hyperplasia 100%
• Terazosin 100%
• Placebo 90%
• Alpha-blockers 60%
• Benign Prostatic Obstruction 60%
• Finasteride 60%
• Adverse Effects 50%
• Symptom Score 40%
• α-antagonist 30%
• Placebo-controlled 20%
• Urinary Symptoms 20%
• Percentage Improvement 20%
• Lower Urinary Tract Symptoms 10%
• Randomized Trial 10%
• Treatment Options 10%
• Headache 10%
• Patient Outcomes 10%
• Active Control 10%
• Symptom Scale 10%
• Patient Characteristics 10%
• Urodynamics 10%
• Dizziness 10%
• Microwave Treatment 10%
• MEDLINE 10%
• Cochrane Library 10%
• Urinary Flow 10%
• Inclusion Criteria 10%
• Efficacy Outcomes 10%
• International Prostate Symptom Score 10%
• Asthenia 10%
• Data Pooling 10%
• Urologic Symptoms 10%
• Specialized Databases 10%
• Flow Measuring 10%
• Treatment Discontinuation 10%
• Tamsulosin 10%
• Bothersome Symptoms 10%
• Urine Flow Rate 10%
• Postural Hypotension 10%
• American Urological Association Symptom Score 10%
• Fold Increase 10%
• Urological Symptoms 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Placebo 100%
• Prostate Hypertrophy 100%
• Terazosin 100%
• Obstruction 54%
• Alpha Adrenergic Receptor Blocking Agent 54%
• Finasteride 54%
• Tamsulosin 9%
• Headache 9%
• Side Effect 9%
• Dizziness 9%
• Orthostatic Hypotension 9%
• Asthenia 9%
• Lower Urinary Tract Symptom 9%

Neuroscience

• Hyperplasia 100%
• Placebo 100%
• Terazosin 100%
• Alpha Blocker 54%
• Finasteride 54%
• Adverse Effect 45%
• Urological 18%
• Headache 9%
• Tamsulosin 9%